Ensitrelvir

Background

Ensitrelvir, an oral antiviral, is being investigated for its potential to address persistent SARS-CoV-2 particles in long COVID patients, specifically targeting viral replication.

Mechanism of Action

• Ensitrelvir: Inhibits SARS-CoV-2 protease, blocking viral replication and reducing viral load in infected cells (Clinical Study).

Pros and Cons

• Pros: Orally administered and may reduce viral load effectively in patients with persistent SARS-CoV-2.
• Cons: Limited evidence in long COVID use; potential liver interactions necessitate monitoring.

References

1. Clinical Study on Ensitrelvir

‍